Goldman Sachs’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $167M | Buy |
11,556,008
+5,413,052
| +88% | +$77.6M | 0.02% | 762 |
|
|
2025
Q4 | $87.5M | Buy |
6,142,956
+2,358,738
| +62% | +$23.2M | 0.01% | 1083 |
|
|
2025
Q3 | $29.8M | Sell |
3,784,218
-558,537
| -13% | -$3.98M | ﹤0.01% | 1873 |
|
|
2025
Q2 | $24.9M | Buy |
4,342,755
+1,639,178
| +61% | +$10.6M | ﹤0.01% | 1937 |
|
|
2025
Q1 | $22.1M | Buy |
2,703,577
+194,213
| +8% | +$1.8M | ﹤0.01% | 1945 |
|
|
2024
Q4 | $23.6M | Sell |
2,509,364
-680,926
| -21% | -$7.08M | ﹤0.01% | 1959 |
|
|
2024
Q3 | $34.1M | Buy |
3,190,290
+1,707,931
| +115% | +$18.6M | 0.01% | 1575 |
|
|
2024
Q2 | $14.7M | Buy |
1,482,359
+140,469
| +10% | +$1.44M | ﹤0.01% | 2141 |
|
|
2024
Q1 | $15.8M | Sell |
1,341,890
-780,855
| -37% | -$9.99M | ﹤0.01% | 2036 |
|
|
2023
Q4 | $30.1M | Sell |
2,122,745
-395,339
| -16% | -$4.49M | 0.01% | 1557 |
|
|
2023
Q3 | $30.6M | Sell |
2,518,084
-278,037
| -10% | -$3.59M | 0.01% | 1441 |
|
|
2023
Q2 | $35.1M | Buy |
2,796,121
+885,390
| +46% | +$10.5M | 0.01% | 1358 |
|
|
2023
Q1 | $21.2M | Buy |
1,910,731
+28,103
| +1% | +$346K | ﹤0.01% | 1770 |
|
|
2022
Q4 | $23M | Sell |
1,882,628
-132,668
| -7% | -$1.49M | 0.01% | 1824 |
|
|
2022
Q3 | $21M | Buy |
2,015,296
+642,826
| +47% | +$7.16M | 0.01% | 1816 |
|
|
2022
Q2 | $14.7M | Sell |
1,372,470
-465,365
| -25% | -$3.83M | ﹤0.01% | 2151 |
|
|
2022
Q1 | $17.4M | Buy |
1,837,835
+500,985
| +37% | +$4.7M | ﹤0.01% | 2162 |
|
|
2021
Q4 | $15.4M | Sell |
1,336,850
-790,905
| -37% | -$8.81M | ﹤0.01% | 2360 |
|
|
2021
Q3 | $20.3M | Buy |
2,127,755
+124,543
| +6% | +$1.27M | ﹤0.01% | 2050 |
|
|
2021
Q2 | $19.3M | Sell |
2,003,212
-61,340
| -3% | -$599K | ﹤0.01% | 2074 |
|
|
2021
Q1 | $20.4M | Sell |
2,064,552
-888,354
| -30% | -$13.8M | 0.01% | 1916 |
|
|
2020
Q4 | $68.2M | Buy |
2,952,906
+415,368
| +16% | +$8.49M | 0.02% | 877 |
|
|
2020
Q3 | $35.8M | Sell |
2,537,538
-145,551
| -5% | -$2.12M | 0.01% | 1260 |
|
|
2020
Q2 | $40.5M | Sell |
2,683,089
-648,098
| -19% | -$7.9M | 0.01% | 1129 |
|
|
2020
Q1 | $30.8M | Sell |
3,331,187
-41,765
| -1% | -$397K | 0.01% | 1200 |
|
|
2019
Q4 | $32.9M | Buy |
3,372,952
+1,007,617
| +43% | +$9.22M | 0.01% | 1465 |
|
|
2019
Q3 | $19M | Buy |
2,365,335
+8,938
| +0.4% | +$97K | 0.01% | 1823 |
|
|
2019
Q2 | $29.4M | Sell |
2,356,397
-94,185
| -4% | -$1.2M | 0.01% | 1556 |
|
|
2019
Q1 | $33.3M | Buy |
2,450,582
+732,392
| +43% | +$8.95M | 0.01% | 1448 |
|
|
2018
Q4 | $16.5M | Buy |
1,718,190
+100,526
| +6% | +$1.11M | 0.01% | 1963 |
|
|
2018
Q3 | $19.6M | Buy |
1,617,664
+524,887
| +48% | +$7.34M | 0.01% | 1941 |
|
|
2018
Q2 | $17.1M | Sell |
1,092,777
-268,664
| -20% | -$4.06M | ﹤0.01% | 2011 |
|
|
2018
Q1 | $20.5M | Sell |
1,361,441
-201,591
| -13% | -$3.07M | 0.01% | 1840 |
|
|
2017
Q4 | $22.5M | Buy |
1,563,032
+385,182
| +33% | +$5.29M | 0.01% | 1850 |
|
|
2017
Q3 | $17.8M | Buy |
1,177,850
+255,944
| +28% | +$3.39M | ﹤0.01% | 2093 |
|
|
2017
Q2 | $9.28M | Buy |
921,906
+144,760
| +19% | +$1.16M | ﹤0.01% | 2565 |
|
|
2017
Q1 | $5.54M | Buy |
777,146
+41,711
| +6% | +$264K | ﹤0.01% | 2848 |
|
|
2016
Q4 | $3.65M | Buy |
735,435
+360,666
| +96% | +$2.5M | ﹤0.01% | 3324 |
|
|
2016
Q3 | $2.77M | Buy |
374,769
+182,682
| +95% | +$1.23M | ﹤0.01% | 3548 |
|
|
2016
Q2 | $1.05M | Sell |
192,087
-874,947
| -82% | -$6.12M | ﹤0.01% | 4143 |
|
|
2016
Q1 | $9.02M | Sell |
1,067,034
-332,760
| -24% | -$2.36M | ﹤0.01% | 2300 |
|
|
2015
Q4 | $13.6M | Buy |
1,399,794
+194,680
| +16% | +$1.75M | ﹤0.01% | 2026 |
|
|
2015
Q3 | $16.9M | Buy |
1,205,114
+6,965
| +0.6% | +$109K | 0.01% | 1840 |
|
|
2015
Q2 | $17M | Sell |
1,198,149
-303,284
| -20% | -$3.65M | 0.01% | 1915 |
|
|
2015
Q1 | $16.3M | Buy |
1,501,433
+376,463
| +33% | +$3.32M | 0.01% | 1902 |
|
|
2014
Q4 | $9.36M | Buy |
1,124,970
+1,037,048
| +1,180% | +$7.12M | ﹤0.01% | 2394 |
|
|
2014
Q3 | $523K | Buy |
87,922
+25,182
| +40% | +$132K | ﹤0.01% | 5225 |
|
|
2014
Q2 | $210K | Buy |
62,740
+18,692
| +42% | +$43.9K | ﹤0.01% | 6164 |
|
|
2014
Q1 | $91K | Sell |
44,048
-8,476
| -16% | -$21.2K | ﹤0.01% | 6422 |
|
|
2013
Q4 | $123K | Sell |
52,524
-19,778
| -27% | -$43.4K | ﹤0.01% | 6196 |
|
|
2013
Q3 | $168K | Sell |
72,302
-2,046
| -3% | -$5.13K | ﹤0.01% | 5967 |
|
|
2013
Q2 | $173K | Buy |
+74,348
| New | +$228K | ﹤0.01% | 5668 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
HI
Goldman Sachs's FOLD Position: Q1 2026 in Review
Goldman Sachs increased its Amicus Therapeutics (FOLD) stake by 88% in Q1 2026, buying an estimated $77.6M and bringing the position to 11,556,008 shares worth $167M. The position accounts for 0.02% of the portfolio, ranked #762.
Goldman Sachs first reported a position in FOLD in Q2 2013 and has held it in 52 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Goldman Sachs held 11,556,008 shares of Amicus Therapeutics worth $167M as of Q1 2026.
- Goldman Sachs bought 5,413,052 Amicus Therapeutics shares in Q1 2026, an estimated $77.6M.
- Amicus Therapeutics made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #762 holding.
- Goldman Sachs first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 52 quarters since.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.